Real World Data

Real-world evidence from year one of iLet commercial availability demonstrates:

  • Reduction in Average Glucose Level – Users experienced a significant and sustainable reduction from baseline HbA1c to follow-up GMI.
  • Increase in TIR – Users experienced a significant and sustainable increase in TIR from baseline therapy*.
  • Low Time in Hypo – The reduction in average glucose and increased time in range were achieved while maintaining a median time <54 mg/dL of 0.28% – about 1/4th the ADA goal of ≤1%.
  • Less Effort. Better Results – The iLet Bionic Pancreas System required much less effort from patients, with improved results consistent across high and low levels of patient engagement.
  • Reduced Burden for Providers – The iLet Bionic Pancreas System positively impacted all patient types, while reducing burden and time spent managing patients.
* Subset  of users with baseline data.
The real-world data presented is observational data. These data do not come from a prospective study designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by baseline HbA1c. Data comes from the first year (5/19/2023–5/18/2024) of real-world iLet usage among those people who had baseline HbA1c data available and who uploaded at least three weeks worth of CGM data to Beta Bionics, Inc., including users who do not meet all criteria in the Indications for Use. Individual user results may vary from the average values shown here. Users were all using Humalog or Novolog.

Low Time in Hypo

The iLet achieved median time <54 mg/dL of 0.28% – about 1/4th the ADA goal

1. Russell, S.J., et al. (2022) A Multicenter Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. The New England Journal of Medicine 2022; 387:1161–117 2. Humalog/Novolog users only. 2. Messer et al., DTT (2022), data on file. 3. Beck et al., DTT (2022), data on file. 4. Kruger et al., DTT (2022), data on file. 5. The real-world data presented are observational data.  These data do not come from a prospective study designed to evaluate the safety or effectiveness of the iLet Bionic Pancreas.  Data comes from a real-world population from first year (5/19/2023–5/18/2024) of iLet usage among those people who had baseline HbA1c data available and who uploaded at least three weeks’ worth of CGM data to Beta Bionics, Inc., including users who do not meet all criteria in the Indications for Use.  Individual user results may vary from the average values shown here.

Less Effort. Better Results

The iLet Bionic Pancreas system required much less effort from patients

The real-world data presented are observational data. These data do not come from a prospective study designed to evaluate the safety or effectiveness of the iLet Bionic Pancreas. Data comes from a real-world population from first year (5/19/2023–5/18/2024) of iLet usage among those people who had baseline HbA1c data available and who uploaded at least three weeks’ worth of CGM data to Beta Bionics, Inc., including users who do not meet all criteria in the Indications for Use. Individual user results may vary from the average values shown here.

The iLet affords all patient types an opportunity for good glucose control

The postmarket surveillance data presented are observational data. These data do not come from a prospective study designed to evaluate the effect of the iLet Bionic Pancreas by the presented subgroups. Data comes from a real-world population from first year (5/19/2023–5/18/2024) of iLet usage among those people who had baseline HbA1c data available and who uploaded at least three weeks’ worth of CGM data to Beta Bionics, Inc., including users who do not meet all criteria in the Indications for Use. Individual user results may vary from the average values shown here.
MM000205_A

Ready to GO BIONIC?

The iLet Bionic Pancreas automatically adjusts to your insulin needs so you don’t have to.

GO BIONIC

Beta Bionics is a people-focused company dedicated to making diabetes easier for everyone, every day.

Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/resouces/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/resources/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Medical Disclaimer – This website is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.

Copyright © 2024 Beta Bionics | Privacy Policy | Safety | Terms of Use | Cookies | Patents  | Code of Conduct